Urolithin A 8-Methyl Ether（CAS No. 35233-17-1）supplier- wholesale

 

Urolithin A 8-Methyl Ether（35233-17-1）Specifications

Product Name	Urolithin A 8-Methyl Ether powder
Chemical Name	3-hydroxy-8-methoxy-6H-benzo[c]chromen-6-one; 3-hydroxy-8-methoxybenzo[c]chromen-6-one; 35233-17-1; MLS001049096; SMR000386929; ChemDiv3_002724; Urolithin A 8-Methyl Ether;
CAS Number	35233-17-1
InChIKey	IGJLBTGXYKPECW-UHFFFAOYSA-N
Molecular Formula	C14H10O4
Molecular Weight	242.23
Monoisotopic Mass	242.057909 g/mol
Melting point	242 °C(Solv: acetic acid (64-19-7))
Boiling point	479.9±38.0 °C(Predicted)
Density	1.375±0.06 g/cm3(Predicted)
Biological Half-Life	N/A
Color	Light Beige to Very Dark Orange Solid
Solubility	Acetone (Slightly, Sonicated) DMSO (Slightly, Sonicated), Methanol (Slightly)
Storage Temperature	Hygroscopic, -20°C Freezer, Under inert atmosphere
Application	Urolithin A 8-Methyl Ether is an intermediate in the synthesis of Urolithin A (U847000), a major metabolite of Ellagitannin and exhibits anti-inflammatory and antioxidant properties.

 

What is Urolithin A 8-Methyl Ether?

Urolithins are secondary metabolites of ellagic acid derived from ellagitannins. In humans ellagitannins are converted by the gut microflora into ellagic acid which is further transformed into urolithins A, urolithin B, urolithin C and urolithin D in the large intestines.

 

Urolithin A 8-Methyl Ether is the intermediate product during the synthesis of Urolithin A. It is a significant secondary metabolite of ellagitannin and possess antioxidant and anti-inflammatory properties.

 

How does Urolithin A 8-Methyl Ether work?

1)Antioxidant properties

Urolithin A 8-Methyl Ether has an antioxidant effect by reducing free radicals, especially reducing the level of reactive oxygen species (ROS) in cells, and inhibiting lipid peroxidation in certain cell types.

 

2)Anti-inflammatory properties

Urolithin A 8-Methyl Ether has anti-inflammatory properties by inhibiting the production of nitric oxide. They specifically inhibit the expression of inducible nitric oxide synthase (iNOS) protein and mRNA that cause inflammation.

 

Urolithin A 8-Methyl Ether benefits

Urolithin A 8-Methyl Ether is an intermediate product in the synthesis process of Urolithin A, and an important secondary metabolite of ellagitannin, with antioxidant and anti-inflammatory properties. As a metabolite of Urolithin A, it may also have some benefits of Urolithin A:

1) Can extends lifespan;

2) Help prevent prostate cancer;

3) Cognitive enhancement;

4) Potential for weight loss

 

The uses of Urolithin A 8-Methyl Ether supplements?

Urolithin A supplements is readily found in the market as ellagitannin-rich food source supplements. As a metabolic product of Urolithin A, Urolithin A 8-Methyl Ether may also be used in supplements.

 

However, there is not much datas about its supplement information, and more research is needed.

 

Reference:

[1]Espín, Juan Carlos; Larrosa, Mar; García-Conesa, María Teresa; Tomás-Barberán, Francisco (2013). “Biological Significance of Urolithins, the Gut Microbial Ellagic Acid-Derived Metabolites: The Evidence So Far”. Evidence-Based Complementary and Alternative Medicine. 2013: 270418.  doi: 1155/2013/270418.  ISSN1741-427X.  PMC 3679724.  PMID 23781257.

[2]Ryu, Dongryeol; Mouchiroud, Laurent; Andreux, Pénélope A; Katsyuba, Elena; Moullan, Norman; Nicolet-dit-Félix, Amandine A; Williams, Evan G; Jha, Pooja; Sasso, Giuseppe Lo (2016). “Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents”. Nature Medicine. 22(8): 879–888. doi:1038/nm.4132. PMID 27400265.

[3]Ishimoto, Hidekazu; Shibata, Mari; Myojin, Yuki; Ito, Hideyuki; Sugimoto, Yukio; Tai, Akihiro; Hatano, Tsutomu (2011). “In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A”(PDF). Bioorganic & Medicinal Chemistry Letters. 21(19): 5901–5904. doi:1016/j.bmcl.2011.07.086. PMID 21843938.

[4]Kasimsetty, S. G., et al.: J. Agri. Food. Chem., 58, 2180 (2010);

[5]Bialonska, D., et al.: J. Agri. Food. Chem., 57, 10181 (2009);